Business Context and Reporting Period
This Form 8-K was filed by Biorestorative Therapies, Inc. on February 20, 2015, reporting events occurring between January 15, 2015, and February 20, 2015. The filing details a series of unregistered equity securities sales and debt conversions.
Key Financial Metrics and Transactions
The filing reports specific capital raising and debt settlement activities rather than standard operating financial metrics (revenue, profit, cash flow).
- Capital Raised (Cash): $390,000 total from two distinct transactions.
- Debt Converted: Approximately $55,984 of outstanding indebtedness (including accrued interest) was settled via stock issuance.
- Services Compensation: Approximately $24,000 in value of stock issued for services.
- Warrant Issuances: Warrants were issued with aggregate estimated values of $62,000 ($40,000 + $22,000).
Material Changes and Transaction Details
The following material definitive agreements and unregistered sales occurred during the reporting period:
- February 20, 2015: Sold 1,000,000 shares to principal shareholder Westbury (Bermuda) Ltd. for $300,000. Included a 5-year warrant for 250,000 shares at $0.75/share (valued at ~$40,000).
- January 15 – February 11, 2015: Issued 333,333 shares for $90,000. Included 5-year warrants for 133,333 shares at exercise prices between $0.40 and $0.75 (valued at ~$22,000).
- January 23 – February 13, 2015: Issued 69,098 shares valued at ~$24,000 for services rendered.
- February 17, 2015: Issued 222,245 shares to settle ~$55,984 of debt.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of unregistered sales. The company relied on Section 4(a)(2) of the Securities Act of 1933 for all transactions, asserting they were private placements to accredited investors without general solicitation.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the current status of the $55,984 debt settlement and whether any residual interest remains.
- Review the exercise terms and expiration dates of the newly issued warrants (250,000 and 133,333 shares).
- Check subsequent filings for any changes in the company's cash position following the $390,000 capital raise.